- Home
- OCUL vs CMPS Comparison
OCUL vs CMPS Comparison
Compare OCUL & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | CMPS |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OCUL | CMPS |
|---|---|---|
| Price | $6.29 | $11.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $26.00 | $23.75 |
| AVG Volume (30 Days) | ★ 3.5M | 2.3M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,990,000.00 | N/A |
| Revenue This Year | $1.71 | N/A |
| Revenue Next Year | $93.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.48 | N/A |
| 52 Week Low | $6.23 | $4.88 |
| 52 Week High | $16.44 | $15.87 |
Technical Indicators
Market Signals| Indicator | OCUL | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 26.48 | 37.45 |
| Support Level | $6.23 | $10.66 |
| Resistance Level | $9.93 | $14.74 |
| Average True Range (ATR) | 0.42 | 0.56 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 15.36 | 15.02 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.